The main therapeutic targets of ICT in prostate cancer are the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) and its ligand (PD-L1) (46, 47). This evidence concerns the gene CTLA4 and prostate cancer.